Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol for fibrosis in discharged COVID-19 patients
NCT04799743Unknown
- Sponsor
- Hong Kong Baptist University
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial in pulmonary fibrosis (PF) comparing Resveratrol group with Placebo group (2 arms). Primary endpoints: Handheld basic spirometry at 9 months, Patient Reported Outcome scores at 9 months and 1 more. Status: unknown.
02
Drugs
resveratrol
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT04799743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799743.